Emyria Ltd (ASX:EMD), a mental health and neurologically focused biotechnology company developing a cutting-edge MDMA-assisted therapy model, has had a busy.
It’s been a difficult quarter for the biotech sector, with economies struggling to recover from high inflation making for a small appetite for risk. The ASX.
The cannabis industry has seen a significant surge in popularity in the last 10 years, leading to enhanced transparency, market understanding and growing.
Emyria Ltd (ASX:EMD) managing director Michael Winlo runs Proactive through the company’s September quarter highlights. EMD generated $1,034,172 of clinical.